

# **EQUITY RESEARCH**

MAPS
RESULTS REVIEW
Press release

BUY
TP 5.2€
Up/Downside: 76%

## **MAPS Continues to Grow**

Yesterday, MAPS released its FY results, which were better than expected in terms of revenue and profitability, but slightly below expectations in terms of cash generation.

MAPS published its FY 2023 results, which showed revenue of  $\epsilon$ 27.5m (vs.  $\epsilon$ 27.1m expected and  $\epsilon$ 24.7m YoY), EBITDA down slightly to  $\epsilon$ 5m (vs.  $\epsilon$ 4.7m expected and  $\epsilon$ 5.9m YoY), net results of  $\epsilon$ 0.9m (vs.  $\epsilon$ 1m expected and  $\epsilon$ 2.7m YoY), and net debt down to  $\epsilon$ 12.5m (vs.  $\epsilon$ 11.9m expected and  $\epsilon$ 13.8m YoY).

Recurring revenue rose to 41% (vs. 39% YoY), with revenue from proprietary solutions accounting for 83% of the total (vs. 84% YoY).

We note that the decline in profitability relative to 2022 was caused by delays in the publication of regulatory decrees and incentives related to the Energy Communities, with the Energy division recording a negative EBITDA of -€0.2m. However, we believe that MAPS is well positioned to take advantage of the imminent growth in this reference market.

Depreciation in 2023 was higher than expected, as were taxes, bringing net results in line with our expectations despite the better EBITDA performance. We have slightly increased our depreciation and tax estimates for the coming years and reduced our financial cost estimates, which had a slightly negative impact on our EPS for the coming years.

We believe that MAPS' growth prospects are strong, particularly for the healthcare and energy BUs, where the company is well positioned to continue to be a leader in digital transformation thanks to its innovative proprietary solutions.

Following the adjustment of market parameters and the improvement in cash generation estimates for the coming years, thanks to better management of expected working capital and slightly more contained capex expenditure, we are adjusting our target price on MAPS to  $\epsilon$ 5.2.

#### Key data

Price (€)	3.0
Industry	Packaged Software
Ticker	MAPS-IT
Shares Out (m)	12.506
Market Cap (m €)	36.9
Average trading volumes	3.011
(k shares / day)	

Source: FactSet

#### Ownership (%)

Fondateurs & Management	54.0
Eiffeil IG	12.7
Maps SpA	1.2
Free float	32.1

Source: TPICAP Midcap estimates

EPS (€)	)	12/24e	12/25e	12/26e
Estimat	es	0.19	0.26	0.32
Change estimate	vs previous es (%)	0.00	0.00	0.00

Source: TPICAP Midcap estimates

Performance (%)	1 <b>D</b>	1 <b>M</b>	YTD
Price Perf	-1.7	-4.8	-5.4
Rel FTSE Italy	-2.5	-10.4	-17.9



Source: FactSet

Consensus FactSet - Analysts:na	12/24e	12/25e	12/26e
Sales	29.9	33.1	na
EBIT	3.8	4.8	na
Net income	2.7	3.5	na

TP ICAP Midcap Estimates	12/23	12/24e	12/25e	12/26e
Sales (m €)	27.5	30.8	33.8	37.2
Current Op Inc (m €)	1.5	3.4	4.4	5.3
Current op. Margin (%)	5.4	11.2	13.2	14.2
EPS (€)	0.07	0.19	0.26	0.32
DPS (€)	0.00	0.00	0.00	0.00
Yield (%)	0.0	0.0	0.0	0.0
FCF (m €)	2.2	2.5	2.6	3.4

Valuation Ratio	12/24e	12/25e	12/26e
EV/Sales	1.5	1.3	1.1
EV/EBITDA	6.5	5.3	4.3
EV/EBIT	13.3	9.7	7.5
PE	15.3	11.2	9-3
Source: TPICAP Midcap	'		

Analyst
Davide Longo
davide.longo@tpicap.com
+33173030977





# FINANCIAL DATA

Income Statement	12/21	12/22	12/23	12/24e	12/25e	12/26e
Sales	21.5	24.7	27.5	30.8	33.8	37.2
Changes (%)	6.0	15.0	11.1	11.8	9.9	10.1
Gross profit	20.4	23.2	25.8	28.9	31.9	35.1
% of Sales	94.7	93.8	93.9	94.0	94.3	94.4
EBITDA	5.0	5.9	5.0	7.0	8.2	9.2
% of Sales	23.4	23.8	18.1	22.7	24.2	24.7
<b>Current operating profit</b>	2.4	3.1	1.5	3.4	4.4	5.3
% of Sales	11.3	12.5	5.4	11.2	13.2	14.2
Non-recurring items	-0.2	-0.2	-0.1	-0.1	-0.1	-0.1
EBIT	2.2	2.9	1.4	3.3	4.3	5.2
Net financial result	-0.2	-0.4	-0.4	-0.5	-0.3	-0.2
Income Tax	0.4	0.2	-0.1	-0.4	-0.7	-1.0
Tax rate (%)	-21.0	-6.5	6.0	15.0	18.0	20.0
Net profit, group share	2.5	2.7	0.9	2.4	3.3	4.0
EPS	0.20	0.22	0.07	0.19	0.26	0.32
Financial Statement	12/21	12/22	12/23	12/24e	12/25e	12/26e
Goodwill	11.7	19.7	19.7	19.7	19.7	19.7
Tangible and intangible assets	7.2	7.3	8.2	8.2	8.0	7.6
Right of Use	0.0	0.0	0.0	0.0	0.0	0.0
Financial assets	0.0	0.2	0.1	0.1	0.1	0.1
Working capital	9.8	12.9	13.2	13.2	14.1	15.0
Other Assets	0.0	0.0	0.0	0.0	0.0	0.0
Assets	28.7	40.1	41.3	41.2	41.9	42.4
Shareholders equity group	18.0	21.0	22.3	26.3	29.6	33.5
Minorities	0.1	0.0	0.0	0.0	0.0	0.0
LT & ST provisions and others	4.9	4.7	5.3	5.3	5.3	5.3
Net debt	4.9	13.8	12.9	8.8	6.2	2.8
Other liabilities	0.8	0.6	0.8	0.8	0.8	0.8
Liabilities	28.7	40.1	41.3	41.2	41.8	42.4
Net debt excl. IFRS 16	2.1	11.8	10.9	6.8	4.2	0.8
Gearing net	0.3	0.7	0.6	0.3	0.2	0.1
Leverage	1.0	2.3	2.6	1.3	0.8	0.3
		5	210	*-5	0.0	0.5
Cash flow statement	12/21	12/22	12/23	12/24e	12/25e	12/26e
CF after elimination of net borrowing costs and taxes	6.6	4.7	5.4	6.0	7.0	7.9
ΔWCR	-3.3	-3.1	0.1	0.0	-0.9	-0.9
Operating cash flow	3.3	1.5	5.6	6.0	6.1	7.0
Net capex	-2.6	-3.0	-3.3	-3.5	-3.5	-3.6
FCF	0.7	-1.5	2.2	2.5	2.6	3.4
Acquisitions/Disposals of subsidiaries	-3.0	-7.8	-1.1	0.0	0.0	0.0
Other investments	0.0	0.0	0.0	0.0	0.0	0.0
Change in borrowings	1.8	6.0	-3.6	0.0	0.0	0.0
Dividends paid	0.0	0.0	0.0	0.0	0.0	0.0
Repayment of leasing debt	0.0	0.0	0.0	0.0	0.0	0.0
Equity Transaction	4.4	0.2	0.4	1.6	0.0	0.0
Others	0.0	0.0	0.0	0.0	0.0	0.0
Change in net cash over the year	2.9	-2.3	-2.0	4.1	2.6	3.4
ROA (%)	8.8%	6.7%	2.3%	5.8%	7.8%	9.3%
ROE (%)	13.9%	12.8%	4.2%	9.1%	11.1%	11.8%
ROCE (%)	13.5%	14.7%	6.6%	13.1%	15.0%	15.7%
1001 (70)	-3.570	-4./ /0	0.070	-01-170	-5.0 /0	13.7 70



## **DISCLAIMER**

#### **Analyst certifications**

This research report (the "Report") has been approved by Midcap, a business division of TP ICAP (Europe) SA ("Midcap"), an Investment Services Provider authorised and regulated by the Autorité de Contrôle Prudentiel et de Résolution ("ACPR"). By issuing this Report, each Midcap analyst and associate whose name appears within this Report hereby certifies that (i) the recommendations and opinions expressed in the Report accurately reflect the research analyst's and associate's personal views about any and all of the subject securities or issuers discussed herein and (ii) no part of the research analyst's or associate's compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst or associate in the Report.

#### Methodology

This Report may mention evaluation methods defined as follows:

- 1. DCF method: discounting of future cash flows generated by the company's operations. Cash flows are determined by the analyst's financial forecasts and models. The discount rate used corresponds to the weighted average cost of capital, which is defined as the weighted average cost of the company's debt and the theoretical cost of its equity as estimated by the analyst.
- 2. Comparable method: application of market valuation multiples or those observed in recent transactions. These multiples can be used as references and applied to the company's financial aggregates to deduce its valuation. The sample is selected by the analyst based on the characteristics of the company (size, growth, profitability, etc.). The analyst may also apply a premium/discount depending on his perception of the company's characteristics.
- 3. Assets and liabilities method: estimate of the value of equity capital based on revalued assets adjusted for the value of the debt.
- 4. Discounted dividend method: discounting of estimated future dividend flows. The discount rate used is generally the cost of capital.
- 5. Sum of the parts: this method consists of estimating the various activities of a company using the most appropriate valuation method for each of them, then realizing the sum of the parts.

#### Conflict of Interests between TP ICAP Midcap and the Issuer

G. Midcap and the Issuer have agreed to the provision by the former to the latter of a service for the production and distribution of the investment recommendation on the said Issuer: Maps

### History of investment rating and target price - Maps





### **Distribution of Investment Ratings**

Rating	Recommendation Universe*	Portion of these provided with investment
		banking services**
Buy	80%	62%
Hold	18%	63%
Sell	1%	ο%
Under review	1%	100%

Midcap employs a rating system based on the following:

Buy: Expected to outperform the markets by 10% or more over a 6 to 12 months horizon.

<u>Hold</u>: expected performance between -10% and +10% compared to the market over a 6 to 12 months horizon.

<u>Sell</u>: Stock is expected underperform the markets by 10% or more over a 6 to 12 months horizon.

The history of ratings and target prices for the Issuers covered in this report are available on request at https://researchtpicap.midcapp.com/en/disclaimer.





#### General Disclaimer

This Report is confidential and is for the benefit and internal use of the selected recipients only. No part of it may be reproduced, distributed, or transmitted without the prior written consent of Midcap

This Report is published for information purposes only and does not constitute a solicitation or an offer to buy or sell any of the securities mentioned herein. The information contained in this Report has been obtained from sources believed to be reliable and public, Midcap makes no representation as to its accuracy or completeness. The reference prices used in this Report are closing prices of the day before the publication unless otherwise stated. All opinions expressed in this Report reflect our judgement at the date of the documents and are subject to change without notice. The securities discussed in this Report may not be suitable for all investors and are not intended to recommend specific securities, financial instruments, or strategies to particular clients. Investors should make their own investment decisions based on their financial situation and investment objectives. The value of the income from your investment may vary due to changes in interest rates, changes in the financial and operating conditions of companies and other factors. Investors should be aware that the market price of the securities discussed in this Report may be volatile. Due to the risk and volatility of the industry, the company, and the market in general, at the current price of the securities, our investment rating may not correspond to the stated price target. Additional information regarding the securities mentioned in this Report is available on request.

This Report is not intended for distribution or use by any entity who is a citizen or resident of, or an entity located in any locality, territory, state, country, or other jurisdiction where such distribution, publication, availability, or use would be contrary to or limited by law or regulation. Entity or entities in possession of this Report must inform themselves about and comply with any such restrictions, including MIFID II. This Report is only intended for persons who are Eligible Counterparties or Professional Clients within the meaning of MIFID II regulation. It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. The Report is subject to restricted circulation. The research was conducted in accordance with the provisions of the Charter of good practices for sponsored research. Midcap has adopted effective administrative and organizational arrangements, including "information barriers", to prevent and avoid conflicts of interest regarding investment recommendations. The remuneration of financial analysts who participate in the preparation of the recommendation is not linked to the corporate finance activity.